Strontium ranelate as a possible disease-modifying osteoarthritis drug: a systematic review
AUTOR(ES)
Rodrigues, T.A., Freire, A.O., Bonfim, B.F., Cartágenes, M.S.S., Garcia, J.B.S.
FONTE
Braz J Med Biol Res
DATA DE PUBLICAÇÃO
18/06/2018
RESUMO
Considering that osteoarthritis (OA) is the most prevalent joint disease worldwide, multiple pharmacological treatments have been proposed to alter the articular structure with potential benefit in the progression of the disease. The so-called disease-modifying OA drugs have been frequently investigated but conclusive findings are rare. Strontium ranelate (SrRan) is a drug usually prescribed to treat osteoporosis, with proven effects in decreasing the risk of fractures and possible effect in reducing the progression of OA. The objective of this review was to demonstrate the current panorama of knowledge on the use of SrRan in clinical and experimental models, clarifying its mechanisms of action and describing possible anti-nociceptive and anti-inflammatory effects. The systematic review was based on the PRISMA statement and included articles that are indexed in scientific databases. Fifteen studies were included: seven pre-clinical and eight clinical studies. Despite the limited number of studies, the results suggest a positive effect of SrRan in patients with OA, through changes in functional capacity and reduction of progression of morphological parameters and joint degradation, with moderate quality of evidence for those clinical outcomes. Novel studies are necessary to elucidate the molecular targets of SrRan, focusing on anti-inflammatory effects and histological changes promoted by SrRan, which seemed to reduce the progression of OA in the experimental and clinical studies.
Documentos Relacionados
- Glucosamine: A potential disease-modifying agent in osteoarthritis?
- Endpoints and Analyses to Discern Disease-Modifying Drug Effects in Early Parkinson’s Disease
- Evidence for early disease-modifying drugs in rheumatoid arthritis
- Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes
- Glyceraldehyde-3-phosphate dehydrogenase as a target for small-molecule disease-modifying therapies in human neurodegenerative disorders